“It is truly a great recognition of our clinical data and the potential for our leading drug candidate iCM012 to be able to present results from the successfully concluded Phase 1/2a study at this acknowledged conference,” said Dr. Biglarnia.

The abstract, titled First-in-Human Phase IIa (ATMIRe) Trial of Ex Vivo Allograft Treatment with iCM012 to Mitigate Ischemia-Reperfusion Injury in Kidney Transplantation, will be presented by Dr. Biglarnia on October 26, 2024.

The abstract presents data from the ATMIRe study, a first-in-human, double-blind, placebo-controlled, randomized, single-center Phase 1/2a trial, which evaluated the safety and tolerability of iCM012 solution, 2 mg/mL for ex-vivo treatment of preserved kidneys to minimize ischemia-reperfusion injury and thereby improve short- and long-term outcomes after kidney transplantation.

Patient enrollment was completed in May 2023, and the clinical report, including 3 months of safety data, was completed in December 2023. Follow-up 12 months of safety data was made available during 2024.

For more information, please contact:
Peder Waern, CEO – iCoat Medical AB
E-mail: peder.waern@icoatmedical.com

About iCoat Medical
iCoat Medical is a clinical stage, pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical’s lead candidate iCM012 is developed to improve the outcome of organ transplantations. The company’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund, and Malmö, and is headquartered in Stockholm.

For more information, please visit https://www.icoatmedical.com/sv/.